Testing a New Drug for Juvenile Psoriatic Arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests an investigational drug called Deucravacitinib to see if it can safely and effectively treat Juvenile Psoriatic Arthritis in children. You may be able to join if standard treatments haven't helped enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Juvenile Psoriatic Arthritis.
- You must have at least three joints affected by arthritis.
- You must have tried at least one JPsA medicine for three months or more without success or with side effects.
- Your JPsA diagnosis must have happened after age 5.
- You cannot have other types of Juvenile Idiopathic Arthritis besides JPsA.
- You cannot have had chronic eye inflammation (uveitis) or an episode in the last three months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
This study looks at how safe the medicine deucravacitinib (used for psoriasis) is during pregnancy. It compares pregnant women who took deucravacitinib to those who did not, to see if there are any effects on the baby.
This trial tests adding a new oral medication (deucravacitinib) to your current anti-TNF therapy to see if it helps better control psoriatic arthritis or psoriasis that hasn't improved enough. It may be an option if you still have active symptoms despite being on a stable anti-TNF treatment for at least 6 months.
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
Hear when a new Juvenile Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.